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1  | INTRODUCTION
The	XIV	Banff	Conference	for	Allograft	Pathology	was	held	March	27-	
31,	2017,	 in	Barcelona,	Spain,	 in	conjunction	with	 the	annual	meet-
ing	of	the	Catalan	Society	of	Transplantation.	A	total	of	479	delegates	
from	 23	 countries	 attended	 the	 conference,	 including	 pathologists,	
immunologists,	 physicians,	 surgeons,	 and	 immunogeneticists.	 The	
main	aim	of	the	2017	conference	was	to	revisit	the	current	diagnostic	
criteria	 for	 chronic	T	 cell–mediated	 rejection	 (TCMR),	 especially	 the	
significance	of	inflammation	in	areas	of	interstitial	fibrosis	and	tubu-
lar	 atrophy	 (i-	IFTA).	 In	 addition,	 discussion	 related	 to	 the	 relevance	
and	potential	integration	of	molecular	transplant	diagnostics	into	the	
Banff	 classification	was	 continued	 along	 the	 roadmap	 developed	 at	
the	2015	Banff	meeting.1	This	included	an	update	of	the	criteria	for	as-
sessing	molecular	features	related	to	antibody-	mediated	tissue	injury	
as	 a	 potential	 alternative/complement	 to	 donor-	specific	 antibodies	
(DSAs)	for	diagnosing	antibody-	mediated	rejection	 (ABMR).	 In	align-
ment	with	ongoing	efforts	of	the	American	Society	of	Transplantation	










kidney	 sessions,	 and	 the	 resulting	changes	 to	 the	classification.	The	
main	conclusions	from	the	2017	Banff	liver,	heart,	lung,	pancreas,	and	
vascularized	composite	allograft	sessions	will	be	published	elsewhere.	
The	 next	 XV	 Banff	 meeting	will	 be	 held	 jointly	 with	 the	 American	
Society	of	Histocompatibility	and	Immunogenetics	 in	Pittsburgh,	PA,	
September	23-	27,	2019.
2  | DEFINING ENDPOINTS IN KIDNEY 
TRANSPLANTATION FOR NEXT- 
GENERATION CLINICAL TRIALS: 
PLACE OF THE BANFF SCHEME AND 
COMBINED ENDPOINTS
The	approval	of	novel	drugs	in	the	field	of	kidney	transplantation	has	
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with	potentially	repositionable	drugs	known	already	for	their	adverse	
reaction	profiles.	Acute	rejection	is	also	recognized	as	a	primary	end-
point	 for	 clinical	 trials	 in	 transplantation	 by	 health	 authorities,	 but	
TCMR	and	ABMR	do	not	 have	 the	 same	 impact	 on	 graft	 outcome.	
Furthermore,	the	transplant	community	and	the	industry	aiming	to	in-
troduce	new	agents	are	addressing	these	issues	independently.






regulatory	 agencies	 and	 international	 societies	 to	 define	 realistic	 and	




2017	Banff	 premeeting,	 those	 new	 challenges	were	 addressed	with	 a	
specific	focus	on	histologic,	immunologic,	and	molecular	endpoints.
2.1 | Histopathology as an endpoint
Rejection	 episodes	 confirmed	 by	 histology	 are	 recognized	 as	 the	
cornerstone	 of	 diagnosis	 and	 prognosis	 in	 kidney	 and	 transplanta-
tion	pathology.	However,	the	current	FDA/EMA-	approved	surrogate	
histologic	 endpoint,	 biopsy-	confirmed	 acute	 rejection	 (BCAR),	 is	 no	
longer	 reflecting	 current	 diagnostics	 in	 renal	 transplantation,	where	
the	impact	of	acute	TCMR	on	outcome	has	declined.	As	an	example,	
in	the	BENEFIT	Study,	BCAR	was	used	as	primary	endpoint	for	non-




















2.4 | Potential of innovative combined endpoints
The	participants	in	the	2017	Banff	premeeting	support	a	path	toward	
integrated	diagnostic	 and	prognostication	 systems	by	 exploring	op-
portunities	 provided	 by	 advanced	 data	 and	 applied	 statistics	 from	
the	 field	of	machine	 learning.7	To	 this	end,	 the	Banff	group	 formed	
a	new	working	group	on	surrogate	endpoints	aimed	at	fostering	col-
laboration	with	other	professional	 societies	and	regulatory	agencies	
on	 the	common	goal	 to	develop	a	path	 forward	 to	successful	next-	
generation	 multicenter	 trials	 and	 approval	 of	 novel	 drugs	 in	 solid	
organ	transplantation.




active	TCMR	may	be	manifest	 in	 the	 tubulointerstitial	 as	well	 as	 in	
the	 vascular	 compartment.1	 However,	 the	 current	 Banff	 classifica-
tion	does	not	provide	specific	criteria	regarding	how	tubulointerstitial	
changes	 should	be	 considered	 for	diagnosing	 chronic	 active	TCMR,	
although	Banff	 consensus	 criteria	 for	 semiquantitatively	 scoring	 in-
flammation	in	areas	of	IFTA	(i-	IFTA)	as	a	histologic	lesion	have	been	
established.	Although	potential	problems	 in	scoring	 i-	IFTA	might	be	
anticipated	 as	 scattered	 inflammatory	 cells	 are	 often	 seen	 in	 what	





The	 impact	 of	 i-	IFTA	 on	 graft	 outcomes	was	 first	 suggested	 by	
the	finding	of	Mengel	et	al9	that	total	cortical	 inflammation	(Banff	ti	
score)	was	more	predictive	of	 graft	 loss	 than	 inflammation	 in	nons-








munosuppressive	 therapy	 remains	 an	 important	 question,	 and	 find-
ings	 of	 the	DeKAF	 study	 showed	 that	 the	 effect	 of	 i-	IFTA	on	 graft	
survival	was	not	significantly	affected	by	 treatment	 for	concomitant	
acute	TCMR.10	Still,	data	presented	by	the	Paris	group8	showed	that	
i-	IFTA	 is	 related	 to	 underimmunosuppression,	 and	 both	 this	 group	
and	Nankivell	et	al11	found	that	i-	IFTA	is	typically	preceded	by	TCMR.	
Furthermore,	 the	 frequency	 of	 i-	IFTA	 in	 protocol	 biopsy	 specimens	
has	declined	in	the	era	of	tacrolimus-	based	immunosuppression	com-
pared	with	 that	 of	 cyclosporine-	based	 immunosuppression.11	 Taken	
together,	these	findings	suggest	that	i-	IFTA,	at	least	in	many	instances,	
is	related	to	chronic	underimmunosuppression	and	thus	can	represent	
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TABLE  1 Update	on	active	Banff	working	groups
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active	component	 in	 the	 rejection	process.	 In	other	words,	a	biopsy	
fulfilling	 the	 diagnostic	 criteria	 for	 chronic	 active	TCMR	 should	 not	
be	given	a	second	diagnosis	of	Borderline	or	acute	TCMR.	However,	
biopsies	with	chronic	active	TCMR	can	have	an	additional	diagnosis	
of	ABMR.	 In	 general,	 i-	IFTA	 likely	 reflects	 a	 response	 to	wounding	
of	 injured	nephrons	and	renal	tissue,	as	shown	by	molecular	studies	
showing	that	any	progressing	chronic	kidney	diseases	are	associated	





Clearly,	 i-	IFTA	 is	 not	 a	 specific	 lesion,	 and	 adding	 i-	IFTA	 by	 it-
self,	even	if	moderate	to	severe,	to	the	classification	as	diagnostic	of	
chronic	 active	TCMR	 does	 not	 appear	warranted	 based	 on	 present	
data.	 It	 is	well	 known	 that	many	 other	 disease	 processes,	 including	
BK	 virus	 infection,	 pyelonephritis,	 ABMR,	 recurrent	 glomerulone-
phritis,	and	obstruction,	may	at	some	point	present	with	 i-	IFTA.	The	




changed	 and	 graft	 survival	 improved	with	more	 patients	 presenting	
late	 posttransplantation	with	 i-	IFTA	 requiring	 differential	 diagnostic	
resolution	to	guide	treatment.	Based	on	the	most	recent	data	taking	






















the	 threshold	values	of	 individual	histologic	 lesions	needed	 to	diag-
nose	chronic	active	TCMR,	whether	the	Banff	i-	IFTA	score	or	ti	score	
is	more	predictive	of	graft	outcomes,	association	with	nonadherence	




At	 this	point,	 there	 is	no	borderline	or	 suspicious	category	 for	












in	 Figure	2,	which	 depicts	 3	 other	 biopsy	 specimens	 showing	 i-	IFTA	
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inflammation,	 edema,	 and	 tubulitis	 using	 3	 different	 histologic	 stains	
(hematoxylin	 and	 eosin,	 periodic	 acid–Schiff,	 and	Masson	 trichrome).	
The	silver-	stained	sections	in	Figure	1	show	tubulitis	in	mildly	to	mod-
erately	atrophic	tubules	(best	evident	in	panels	B	and	D),	and	both	of	
these	 biopsy	 specimens	 also	 show	 some	 severely	 atrophic	 tubules.	
The	 latter	 tubules	are	defined	by	having	a	diameter	<25%	of	 that	of	
unaffected	or	minimally	affected	tubules	on	the	biopsy,	often	with	an	
undifferentiated-	appearing,	 cuboidal,	 or	 flattened	 epithelium	 (or,	 in	




lumens,	 although	 the	basement	membranes	of	 the	 latter	may	not	be	
thickened.	Frequently,	severely	atrophic	tubules	will	show	tubulitis	even	
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3.3 | Alternatives to the DSA criterion in 
ABMR diagnosis






of	 ABMR	 diagnosis	 with	 graft	 outcome.22	 Furthermore,	 molecular	
studies	 of	 Gupta	 et	al23	 strongly	 validated	 the	 MVI	 sum	 score	 of	
(g	+	ptc)	≥2	required	for	diagnosis	of	ABMR	by	Banff	2013.	Still,	MVI,	
even	with	(g	+	ptc)	scores	of	≥2	and	as	high	as	5,	is	not	specific	for	
ABMR,23,24	 and	Sis	 et	al24	 found	 that	11%	of	patients	with	biopsy	
specimens	showing	 (g	+	ptc)	=	5	were	DSA	negative.	Nevertheless,	







































In	 such	 instances,	 testing	 for	 non-	HLA	 antibodies	 (eg,	 anti–angio-




incorporation	 of	 C4d-	negative	 ABMR	 into	 the	 Banff	 classification	
in	 2013,14	multiple	 studies	 have	 shown	 that	 C4d	 staining	 in	 peri-
tubular	 capillaries	 by	 immunofluorescence	 (IF)	 on	 frozen	 sections	
or	 immunoperoxidase	 on	 paraffin	 sections	 has	 a	 very	 high	 (>90%)	
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TABLE  5 Revised	Banff	2017	classification	of	antibody-	mediated	rejection	(ABMR)	and	T	cell–mediated	rejection	(TCMR)	in	renal	allografts:	
revisions	highlighted	in	boldface	type
Category 1: Normal biopsy or nonspecific changes












Increased expression of gene transcripts/classifiers in the biopsy tissue strongly associated with ABMR, if thoroughly validated
3.	Serologic	evidence	of	donor-	specific	antibodies	(DSA	to	HLA	or	other	antigens).	C4d staining or expression of validated transcripts/classifiers as 
noted above in criterion 2 may substitute for DSA; however thorough DSA testing, including testing for non-HLA antibodies if HLA antibody 












2. Criterion 1 for active or chronic, active ABMR not met
3. No molecular evidence for ABMR as in criterion 2 for active and chronic, active ABMR
4.	No	acute	or	chronic	active	TCMR,	or	borderline	changes





















304  |     HAAS et Al.
ABMR	 classification	 in	 Banff	 2013.14	 Since	 that	 time,	 combina-
tions	 of	 transcripts	 have	 been	 introduced	with	 far	 greater	 spec-
ificity	 for	 ABMR,17-20	 although	 these	 molecular	 tests	 admittedly	
still	have	 limitations	and	are	not	yet	approved	as	diagnostic	tests	
by	 regulatory	bodies.	Hidalgo	et	al31	 introduced	a	 “DSA-	specific”	
transcript	 set	 (DSASTs)	 of	 mRNAs	 differentially	 expressed	 in	 bi-




A	more	 specific	molecular	marker	 for	ABMR	 is	 the	ABMR	classi-







be	 used	 to	 satisfy	 criterion	 3	 in	 the	 diagnosis	 of	 ABMR,	 similar	
to	 C4d	 (Table	5).	 It	 should	 be	 stressed	 that	 for	 this	 to	 be	 done	
at	 any	 given	 center,	 the	 cut-	off	 value	 of	 such	molecular	 assess-
ment	 in	 the	diagnosis	of	ABMR	must	be	 independently	validated	
at	each	center	at	 this	point	 in	 time.	With	 technologies	becoming	
available	 to	 derive	 the	 molecular	 assessment	 (classifier	 or	 gene	
set)	from	formalin-	fixed	paraffin-	embedded	(FFPE)	routine	biopsy	
specimens,32,33	 multicenter	 validation	 should	 become	 feasible	 in	
the	near	future	through	collaborative	efforts	of	the	ongoing	Banff	
working	groups	(Table	1).












ABMR,	 keeping	 the	 footnote	 from	 Banff	 2013	 (Table	5).	 A	major-








Grade IA Interstitial inflammation involving >25% of the total cortex (ti score 2 or 
3) and >25% of the sclerotic cortical parenchyma (i-IFTA score 2 or 3) 
with moderate tubulitis (t2) involving 1 or more tubules, not including 
severely atrophic tubules5; other known causes of i-IFTA should be 
ruled out
Grade IB Interstitial inflammation involving >25% of the total cortex (ti score 2 or 
3) and >25% of the sclerotic cortical parenchyma (i-IFTA score 2 or 3) 
with severe tubulitis (t3) involving 1 or more tubules, not including 
severely atrophic tubules5; other known causes of i-IFTA should be 
ruled out
Grade II1 Chronic allograft arteriopathy (arterial intimal fibrosis with mononuclear 














on	 the	biopsy,	 an	undifferentiated-	appearing,	 cuboidal	or	 flattened	epithelium,	and	pronounced	wrinkling	and/or	 thickening	of	 the	 tubular	basement	
membrane.
TABLE  5  (Continued)




active	 ABMR,	 which	 most	 often	 represents	 a	 continuum	 of	 the	
smoldering	form	should	the	 latter	not	be	diagnosed	and	treated	 in	








pathology	 report	 indicates	 ongoing	 disease	 activity	 highlighted	 by	
MVI	with	or	without	concomitant	chronic	remodeling	(TG,	PTCBML,	
IFTA,	cv)	of	the	allograft.

























ated	with	 TCMR15,16,18,20	may	 also	 prove	 useful	 in	 differentiating	
borderline	infiltrates	 likely	to	 lead	to	development	of	overt	TCMR	
and/or	graft	fibrosis	from	those	that	are	not,	as	well	as	evaluating	
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laboratory	 performing	 such	 testing,	 and	 gene	 expression	 thresholds	
significantly	associated	with	ABMR,	TCMR,	or	other	lesions	may	well	





valuable	 information	 for	 improving	 the	 classification	 and	prognostic	
assessment	of	rejection.19,37-39
As	 discussed,	 the	 changes	 made	 to	 the	 Banff	 classification	




ing	 report	will	 serve	 as	 a	 stimulus	 for	 studies	 testing	 the	 validity	
of	the	revised	diagnostic	criteria	for	TCMR	and	ABMR	with	respect	
to	predicting	patient	outcomes,	as	well	as	studies	directly	applying	
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